Evidence map›Paper›PMID 36968227›Full record

ArticleCancer research communications2023

Inhibiting IGF1R-mediated Survival Signaling in Head and Neck Cancer with the Peptidomimetic SSTN

Noah A Stueven, DeannaLee M Beauvais, Rong Hu, Randall J Kimple, Alan C Rapraeger

Open access · goldFull text read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer research communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Noah A StuevenDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-4651-8070
DeannaLee M BeauvaisDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-4575-1564
Rong HuDepartment of Pathology and Laboratory Medicine, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0002-1502-9848
Randall J KimpleDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0001-8336-8000
Alan C RapraegerDepartment of Human Oncology, University of Wisconsin-Madison, Madison, Wisconsin.ORCID 0000-0003-1719-3286
University of Wisconsin–Madison · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Justine Yang Bruce · 1985 to 2026
$142.6M
Project 3: Modulation of the head and neck tumor immune microenvironment by targeting the TAM family of receptorsP50CA278595 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI David J Beebe · 2022 to 2026
$12.5M
Project 4: Role of Receptor Tyrosine Kinase AXL in HNSCC Therapy ResistanceP50DE026787 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI HARARI, PAUL M · 2016 to 2020
$10.8M
Signaling role of syndecans in HER2+ and triple negative breast cancerR01CA163662 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAPRAEGER, ALAN C · 2013 to 2017
$2.0M
A kinase-independent role for EGFR in p38MAPK suppression and S-phase progression in head and neck cancerR01DE028341 · NIDCR · UNIVERSITY OF WISCONSIN-MADISON · PI RAPRAEGER, ALAN C · 2020 to 2022
$1.4M
NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA163662NIDCR NIH HHS P50 DE026787NIDCR NIH HHS R01 DE028341
6 · The paper itself

Abstract

Previous studies have shown that the type I IGFR (IGF1R) suppresses apoptosis when it is autoactivated by coupling its extracellular domain to a matrix adhesion receptor complex consisting of syndecan-1 (Sdc1) and αvβ3 or αvβ5 integrin. We now report that head and neck squamous cell carcinoma (HNSCC) relies on this receptor complex. Disruption of the complex in HNSCC cells Significance: A newly developed biomarker reveals upregulation of an antiapoptotic IGF1R-integrin-syndecan receptor complex in head and neck cancer and documents disruption of the complex in patient-derived tumor xenografts (PDX) treated with the inhibitor SSTN

Indexed as

Head and Neck NeoplasmsPeptidomimeticsAnimalsHumansMicePeptidesReceptor, IGF Type 1Signal TransductionSquamous Cell Carcinoma of Head and NeckIGF1R protein, humanPeptidesPeptidomimeticsReceptor, IGF Type 1

Identifiers

PMID36968227
PMCPMC10035507
OpenAlexW4313557398

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read52
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.